The press service of the French pharmaceutical company Sanofi reported that the company would limit commercial activities and clinical trials in Russia and Belarus.
It is noted that the supply of vital medical drugs produced will not be interrupted.
The decision of the Company’s restriction implies, in particular, the refusal of advertising costs and marketing products. At the same time, Sanofi, stopping a set of patients to participate in clinical trials, will continue treatment and examination of patients involved in its programs.